Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. You can set up to four test reminders, three of which can be timed and one post meal test reminders. CareSens N Technical Information Meter is restricted for use in people with needle phobia, paediatrics, visual impairments and physical impairments requiring single-handed use

Sanofi: Insuman (recombinant human insulin): permanent discontinuation of 3 presentations – end of supply in 2020 letter The CareSens N meets and exceeds the 2013 ISO standards for blood glucose meter accuracy with 99% of results meeting the 2013 accuracy criteria. Sample loading – avoid spoiled tests

MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) For your patients with diabetes who are currently prescribed Insuman® Basal: A step-by-step guide on how to use Insuman® Basal SoloStar. For your patients with diabetes who are currently prescribed Toujeo® SoloStar: A video on how to use Toujeo® SoloStar. Medicines suitable for routine use within primary care. Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians.

The CareSens N Blood Glucose Monitor offers easy and accurate testing and there’s no coding required. Formulary for the listed indications that meet the NHSE criteria as proposed in annex A of the following linked guidance document

Meal markers can be attached to tests to show which tests were pre-meal tests and which were post-meal tests. The managed introduction of biosimilar Insulin Glargine (Semglee®▼) for patients with Type 2 Diabetes There will no longer be a requirement to complete Blueteq forms for initiation or continuation of Freestyle Libre by specialist diabetes teams. Refer to BCWB CCG memo (1st October 2021) Training on the correct use, storage and recording of the readings should be provided by the issuing clinician NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A video on how to use Toujeo® DoubleStar. Firmly insert a new lancet into the lancet holder. Hold the lancet firmly. Gently twist to pull off the protective disk. Save disk to recap lancet after use. Replace lancet device tip. SLGT2 inhibitors are not to beused inprimary care for type 1 diabetes until further local guidance becomes available MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness

Insuman Comb 25 - Insuman® Comb 25 100 IU/mL- suspension for injection in a vial - Subcutaneous use. NICE NG17: Type 1 diabetes in adults: diagnosis and management - Recommendations Section 1.7.5 -When starting an insulin for which a biosimilar is available, use the product with the lowest acquisition cost. [2021] Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.

See DMMAG Type 2 Diabetes Mellitus - Guideline for the choice of oral and non-insulin antidiabetic agents for adults Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management servicewith a commercial agreement in place.Caution - retinopathy. Do not use in patients withpre-proliferative/proliferativeretinopathy (R2/R3 grade)or maculopathy (M1)or who are undergoing or awaiting eye laser or intravitreal treatments. Ensure all patients areup-to-date with theirretinopathy screening programmeprior to initiation of semaglutide, and thattheyattend their annual screening whilst on treatment. Victoza (liraglutide) 1.2mg daily dose is appropriate for most patients . Victoza 1.8mg daily is NON-FORMULARY. Patients requiring doses higher than Victoza (liraglutide) 1.2mg should be switched to an alternative GLP-1 receptor agonist e.g. Trulicity (dulaglutide) 1.5 mg weekly or Ozempic (semaglutide) 1mg weekly. Restricted use: Meter is restricted for use in patients with needle phobia, paediatrics, visual impairments and physicial impairments requiring single-handed use To avoid the use of an insulin pump in patients with Type 1 diabetes who have nocturnal/severe hypoglycaemia as defined in NICE TA 151 OR recurrent DKA despite good compliance with current insulin regime For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A guide on how to use Toujeo® DoubleStar.